New approaches to cancer immunotherapy have been developed, showing the ability to
harness the immune system to treat and eliminate cancer. For many solid tumors, therapy …

In recent years, the notion of “one gene makes one protein that functions in one signaling
pathway” in mammalian cells has been shown to be overly simplistic. Recent genome-wide …

In 2012, ponatinib (Iclusig®), an orally available pan-BCR-ABL tyrosine kinase inhibitor
(TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug …

The inhibition of kinases has been pursued by the pharmaceutical industry for over 20 years.
While the locations of the sites that bind type II and III inhibitors at or near the adenosine 5 …

Common cancer theories hold that tumor is an uncontrolled somatic cell proliferation caused
by the progressive addition of random mutations in critical genes that control cell growth …

Chronic myeloid leukemia (CML) is a type of blood cancer that is known to affect
hematopoietic stem cells. The presence of the Philadelphia chromosome (Ph+) is the major …

Imatinib is the first molecularly targeted compound for chronic myeloid leukemia (CML)
capable to inhibit BCR-ABL kinase activity. However, recent clinical evidence indicates that …

The old-fashioned anticancer approaches, aiming at arresting cancer cell proliferation
interfering with non-specific targets (eg DNA), have been replaced, in the last decades, by …

Patients with chronic myeloid leukemia (CML) can be treated with oral tyrosine kinase
inhibitors (TKIs). Pharmacist-led oral chemotherapy programs (POCPs) can improve TKI …

c-Src and Bcr-Abl are two cytoplasmatic tyrosine kinases (TKs) involved in the development
of malignancies. In particular, Bcr-Abl is the etiologic agent of chronic myeloid leukemia …